Treating diabetic retinopathy by tackling growth factor pathways

Current Opinion in Investigational Drugs

Volumn 6, Issue 4, 2005, Pages 395-409

  Chiarelli, Francesco ^a   Giannini, Cosimo ^a   Di Marzio, Daniele ^a   Mohn, Angelika ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Diabetic retinopathy; Growth factors; IGF 1; Medical treatment; PKC; VEGF

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; APTAMER; CELL RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE; GROWTH FACTOR; GROWTH HORMONE; HYPOTHALAMUS RELEASE INHIBITING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; L 779976; MIDOSTAURIN; NITRIC OXIDE SYNTHASE; OCTREOTIDE; PADGEM PROTEIN; PARVOVIRUS VECTOR; PEGAPTANIB; PEGVISOMANT; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RHUFAB; RUBOXISTAURIN; SEGLITIDE; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; X LINKED INHIBITOR OF APOPTOSIS;

ANTIANGIOGENIC ACTIVITY; BLOOD PRESSURE REGULATION; BLOOD VESSEL PERMEABILITY; CELL ADHESION; CHEMICAL ANALYSIS; CLINICAL TRIAL; DIABETIC RETINOPATHY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DNA SYNTHESIS; DOSE RESPONSE; DRUG ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG REEXPOSURE; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GENE THERAPY; GLYCATION; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; LASER COAGULATION; MACROGLIA; METABOLIC REGULATION; MICROANEURYSM; MICROGLIA; MONOTHERAPY; MORBIDITY; NAUSEA; NERVE CELL; NONHUMAN; ONSET AGE; PATHOGENESIS; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RETINA BLOOD FLOW; RETINA NEOVASCULARIZATION; REVIEW; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; VISUAL ACUITY; VOMITING;

ANIMALS; DIABETIC RETINOPATHY; FEMALE; GROWTH SUBSTANCES; HUMANS;

EID: 17644415720     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (191)

1. Microvascular and acute complications in IDDM patients: The EURODIAB IDDM Complications study. Diabetologia (1994) 37 3):278-285.
2. Danne T, Kordonouri O, Casani A, Tumini S, Chiarelli F: Recent advances on the pathogenesis of both diabetic retinopathy and nephropathy with particular reference to children and adolescent with type 1 diabetes. Diabetes Nutr Metab (1999) 12(2):136-144.
3. Center for Disease and Control and Prevention: National Diabetes Fact Sheet: National estimates on diabetes. (2003). http://www.cdc.gov/diabetes/pubs/estimates.htm
4. Chiarelli F, Mohn A: Angiopathy in children with diabetes. Minerva Pediatr (2002) 54(3):187-201.
5. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R: Retinopathy in diabetes. Diabetes Care (2004) 27(Suppl 1):S84-S87.
6. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie-House Classification. ETDRS report number 10. Ophthalmology (1991) 98(5 Suppl):786-806.
7. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology (1991) 98(5 Suppl):823-833.
8. Schmetterer L, Wolzt M: Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia (1999) 42(4):387-405.
9. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol (1984) 102(4):520-526.
10. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology (1995) 102(1):7-16.
11. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 414(6865):813-820.
12. Sone H, Deo BK, Kumagai AK: Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. Invest Ophthalmol Vis Sci (2000) 41(7):1876-1884.
13. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R: Diabetic retinopathy. Diabetes Care (1998) 21(1):143-156.
14. Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW, Adamis AP: Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci (2000) 41(5):1153-1158.
15. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA: Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci (1996) 37(5):886-897.
16. Cogan DG, Toussaint D, Kuwabara T: Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol (1961) 66 366-378.
17. Schmetterer L, Wolzt M: Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia (1999) 42(4):387-405.
18. McLeod DS, Lefer DJ, Merges C, Lutty GA: Enhanced expression of intracellular adhesion molocule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol (1995) 147 3):642-653.
19. Cunha-Vaz J, Faria de Abreu JR, Campos AJ: Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol (1975) 59(11):649-656.
20. Davidson MK, Russ PK, Glick GG, Hoffman LH, Chang MS, Haselton FR: Reduced expression of the adherens junction protein cadherin-5 in a diabetic retina. Am J Ophthalmol (2000) 129 2):267-269.
21. Speiser P, Gittelsohn AM, Patz A: Studies on diabetic retinopathy. 3. Influence of diabetes on intramural pericytes. Arch Ophthalmol (1968) 80(3):332-337.
22. Ansari NH, Zhang W, Fulep E, Mansour A: Prevention of pericyte loss by trolox in diabetic rat retina. J Toxicol Environ Health A (1998) 54(6):467-475.
23. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G: Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J Clin Invest (1998) 101 9):1905-1915.
24. Booth G, Stalker TJ, Lefer AM, Scalia R: Elevated ambient glucose induces acute inflammatory events in the microvasculature: Effects of insulin. Am J Physiol - Endocrinol Metab (2001) 280(6):E848-E856.
25. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes (1998) 47(12):1953-1959.
26. Barber AJ, Antonetti DA, Gardner TW: Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. Invest Ophthalmol Vis Sci (2000) 41 11):3561-3568.
27. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem (1999) 274(33):23463-23467.
28. Antonetti DA, Lieth E, Barber AJ, Gardner TW: Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol (1999) 14(4):240-248.
29. Abbott NJ, Revest PA, Romero IA: Astrocyte-endothelial interaction: Physiology and pathology. Neuropathol Appl Neurobiol (1992) 18(5):424-433.
30. Rungger-Brandle E, Dosso AA, Leuenberger PM: Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci (2000) 41(7):1971-1980.
31. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM: Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes (1998) 47 5):815-820.
32. Lieth E, LaNoue KF, Antonetti DA, Ratz M: Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. Exp Eye Res (2000) 70(6):723-730.
33. Mizutani M, Gerhardinger C, Lorenzi M: Muller cell changes in human diabetic retinopathy. Diabetes (1998) 47 3):445-449.
34. Zeng XX, Ng YK, Ling EA: Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci (2000) 17(3):463-471.
35. Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL, Stacker SA, Cooper ME: Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest (1998) 78(8):1017-1027.
36. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med (1993) 329(14):977-986.
37. The Diabetes Control and Complications Trial Research Group: Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology (1995) 102(4):647-661.
38. The Diabetes Control and Complications Trial Research Group: Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. J Am Med Assoc (1996) 276(17):1409-1415.
39. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352(9131):837-853.
40. Chiarelli F, Santilli F, Mohn A: Role of growth factors in the development of diabetic complications. Horm Res (2000) 53 2):53-67.
41. Eriksson U, Alitalo K: Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol (1999) 237:41-57.
42. Ferrara N: Vascular endothelial growth factor: Molecular and biological aspects. Curr Top Microbiol Immunol (1999) 237 1-30.
43. Persico MG, Vincenti V, DiPalma T: Structure, expression and receptor-binding properties of placenta growth factor (PIGF). Curr Top Microbiol Immunol (1999) 237:31-40.
44. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U: Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA (1998) 95(20):11709-11714.
45. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol (1995) 113(12):1538-1544.
46. Yang Q, Zwijsen A, Slegers H: Purification and characterization of VEGF/VPF secreted by human retinal pigment epithelial cells. Endothelium (1994) 2:73-85.
47. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 15 7):1751.
48. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci (2001) 42(10):2408-2413.
49. Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, Liao JK, Adamis AP: VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci (1999) 40(8):1808-1812.
50. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP: Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol (2000) 156(5):1733-1739.
51. Hofman P, Blaauwgeers HG, Vrensen GF, Schlingemann RO: Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A-induced retinopathy in monkeys. Ophthalmic Res (2001) 33(3):156-162.
52. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP: Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 103 11):1820-1828.
53. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med (1995) 1(10):1024-1028.
54. Gerber HP, Dixit V, Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 273 21):13313-13316.
55. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 273(46):30336-30343.
56. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest (1999) 103(2):159-165.
57. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA (1996) 93(25):14765-14770.
58. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev (1997) 18(1):4-25.
59. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C et al: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 380 6573):435-439.
60. Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (1995) 376(6535):66-70.
61. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (1995) 376 6535):62-66.
62. Fujio Y, Walsh K: Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem (1999) 274 23):16349-16354.
63. Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG, Kerbel RS: Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun (1999) 264(3):781-788.
64. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA (2002) 99(7):4349-4354.
65. Sone H, Kawakami Y, Okuda Y, Sekine Y, Honmura S, Matsuo K, Segawa T, Suzuki H, Yamashita K: Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia (1997) 40(6):726-730.
66. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K:The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest (1996) 74(4):819-825.
67. Boulton M, Foreman D, Williams G, McLeod D: VEGF localisation in diabetic retinopathy. Br J Ophthalmol (1998) 82(5):561-568.
68. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW: Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci (1997) 38(1):36-47.
69. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J: Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol (1996) 114(8):971-977.
70. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E: Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol (1996) 80 3):241-245.
71. Smith G, McLeod D, Foreman D, Boulton M: Immunolocalisation of the VEGF receptors Flt-1, KDR, and Flt-4 in diabetic retinopathy. Br J Ophthalmol (1999) 83 4):486-494.
72. Schlingemann RO, Hofman P, Vrensen GF, Blaauwgeers HG: Increased expression of endothelial antigen PAL-E in human diabetic retinopathy correlates with microvascular leakage. Diabetologia (1999) 42(5):596-602.
73. Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen GF, Schlingemann RO: Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci (2002) 43(3):849-857.
74. Campochiaro PA: Retinal and choroidal neovascularization. J Cell Physiol (2000) 184(3):301-310.
75. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL: Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes (1995) 44(1):98-103.
76. Miller JW, Adamis AP, Aiello LP: Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev (1997) 13(1):37-50.
77. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA (1995) 92(3):905-909.
78. Shinoda K, Ishida S, Kawashima S, Wakabayashi T, Matsuzaki T, Takayama M, Shinmura K, Yamada M: Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol (1999) 83(7):834-837.
79. Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor ZJ: Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol (1996) 80(4):363-366.
80. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol (1994) 118(4):445-450.
81. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med (1994) 331(22):1480-1487.
82. Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda E: Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci (2000) 41(7):1649-1656.
83. Shinoda K, Ishida S, Kawashima S, Wakabayashi T, Uchita M, Matsuzaki T, Takayama M, Shinmura K, Yamada M: Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. Curr Eye Res (2000) 21(2):655-661.
84. Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology (1991) 98(5 Suppl):766-785.
85. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES et al: VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med (2003) 198(3):483-489.
86. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med (1996) 2(9):992-997.
87. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol (1998) 111(1):1-6.
88. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA: Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci (1994) 35(1):101-111.
89. 2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci (1995) 36 10):2063-2070.
90. Dorey CK, Aouididi S, Reynaud X, Dvorak HF, Brown LF: Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Ophthalmol (1996) 114(10):1210-1217.
91. Donahue ML, Phelps DL, Watkins RH, LoMonaco MB, Horowitz S: Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy. Curr Eye Res (1996) 15(2):175-184.
92. McLeod DS, Brownstein R, Lutty GA: Vaso-obliteration in the canine model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci (1996) 37(2):300-311.
93. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 16(9):4604-4613.
94. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP: Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF. J Clin Invest (2002) 109(6):805-815.
95. Williams B, Gallacher B, Patel H, Orme C: Glucose-induced protein kinase C activation regulates vascular permeability factor MRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes (1997) 46(9):1497-1503.
96. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP: Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest (1998) 101(6):1219-1224.
97. Frank S, Hubner G, Breier G, Longaker MT, Greenhaigh DG, Werner S: Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem (1995) 270(21):12607-12613.
98. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K: Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem (1994) 269(9):6271-6274.
99. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB: Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem (1996) 271 46):29483-29488.
100. Ben-Av P, Crofford LJ, Wilder RL, Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS Lett (1995) 372(1):83-87.
101. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interieukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem (1996) 271(2):736-741.
102. Eyetech Study Group: Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (2002) 22(2):143-152.
103. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA (1995) 92(23):10457-10461.
104. Chen HX, Gore-Langton RE, Cheson BD: Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Huntingt) (2001) 15 8):1017, 1020, 1023-1026.
105. Eyetech Study Group: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology (2003) 110(5):979-986.
106. Housey GM, O'Brian CA, Johnson MD, Kirschmeier P, Weinstein IB: Isolation of cDNA clones encoding protein kinase C: Evidence for a protein kinase C-related gene family. Proc Natl Acad Sci USA (1987) 84(4):1065-1069.
107. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (1992) 258(5082):607-614.
108. Newton AC: Regulation of protein kinase C. Curr Opin Cell Biol (1997) 9(2):161-167.
109. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA (1992) 89 22):11059-11063.
110. Koya D, King GL: Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 47 6):859-866.
111. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes (1994) 43(9):1122-1129.
112. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD: Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure. Am J Physiol - Renal Physiol (2000) 278 4):F667-F675.
113. 2 activation. Metabolism (1997) 46(1):41-47.
114. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: A specific vascular action of insulin. Circulation (2000) 101(6):676-681.
115. Yokota T, Ma RC, Park JY, Isshiki K, Sotiropoulos KB, Rauniyar RK, Bornfeldt KE, King GL: Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes (2003) 52(3):838-845.
116. Takagi C, Bursell SE, Lin YW, Takagi H, Duh E, Jiang Z, Clermont AC, King GL: Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci (1996) 37(12):2504-2518.
117. Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K, Yamauchi T, Ha SW, Meier M, Rhodes CJ, King GL: Induction of endothelin-1 expression by glucose: An effect of protein kinase C activation. Diabetes (2000) 49(7):1239-1248.
118. Evans T, Deng DX, Chen S, Chakrabarti S: Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes (2000) 49 4):662-666.
119. Booth G, Stalker TJ, Lefer AM, Scalia R: Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes (2002) 51(5):1556-1564.
120. Abiko T, Abiko A, Clermont AC, Shoelson B, Horio N, Takahashi J, Adamis AP, King GL, Bursell SE: Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: Role of oxidants and protein kinase-C activation. Diabetes (2003) 52 3):829-837.
121. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Miyamoto K, Nishiwaki H, Honda Y, Ogura Y: PKC-β inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci (2000) 41(9):2702-2706.
122. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest (1996) 98(9):2018-2026.
123. Feener EP, Xia P, Inoguchi T, Shiba T, Kunisaki M, King GL: Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Contrib Nephrol (1996) 118:180-187.
124. Pieper GM, Riaz-ul-Haq: Activation of nuclear factor-κB in cultured endothelial cells by increased glucose concentration: Prevention by calphostin C. J Cardiovasc Pharmacol (1997) 30 4):528-532.
125. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R: Hyperglycemia-induced activation of nuclear transcription factor κB in vascular smooth muscle cells. Diabetes (1999) 48 4):855-864.
126. Takahara N, Clermont A, Kagokawa H, Takahara H, Kurihara H, Bursell S, King GL: Transgenic mice overexpressing protein kinase C β isoform mimicked the early changes of diabetes. Diabetes (1999) 48:Abs 0594.
127. Way KJ, Chou E, King GL: Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci (2000) 21(5):181-187.
128. Seo MS, Kwak N, Ozaki H, Yamada H, Okamoto N, Yamada E, Fabbro D, Hofmann F, Wood JM, Campochiaro PA: Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol (1999) 154(6):1743-1753.
129. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T: PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des (2000) 15(1):17-28.
130. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 19(5):1485-1492.
131. Campochiaro PA: Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci (2004) 45(3):922-931.
132. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH 3rd, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Faul MM et al: (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1 H,13 H-dibenzo[e,k]pyrrolo[3,4-h [1,4,13]oxadiaza-cyclohexadecene-1,3(2H-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C β. J Med Chem (1996) 39(14):2664-2671.
133. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, King GL et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor. Science (1996) 272(5262):728-731.
134. Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibiton of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci (1998) 39(1):171-179.
135. Demolle D, de Suray JM, Onkelinx C: Pharmacokinetics and safety of multiple oral dose of LY333531, a PKCβ inhibitor, in healthy subjects. Clin Pharmacol Ther (1999) 65(2):189.
136. Demolle D, de Suray JM, Vandenhende F, Onkelinx C: LY33531 single escalating oral dose study in healthy volunteers. Diabetologia (1998) 41(Suppl 1):A354.
137. Aiello LP, Bursell S, Dervries T, Alatorre C, King G, Ways K: Protein kinase C selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. Diabetes (1999) 48:Abs 0082.
138. Aiello L, Davis M, Milton RC, Sheetz MJ, Arora V, Vinati L: Initial results of the protein kinase C β inhibitor Diabetic Macular Edema Study (PKC-DMES). Diabetologia (2003) 46(Suppl 2):A42.
139. Davis MD, Aiello LP, Milton R, Sheetz M, Arora V, Vignati L, PKC-DRS and PKC-DMES Study Group: Diabetic retinopathy and macular edema progression rates in recent placebo-controlled clinical trials. Diabetes (2003) 52:Abs 858-P.
140. Mifton R, Aiello L, Davis M, Arora V, Vignati L, PKC-DRS and PKC-DMES Study Group: Initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS). Diabetes (2003) 52:Abs 544-P.
141. Poulsen JE: Recovery from retinopathy in a case of diabetes with Simmonds'disease. Diabetes (1953) 2(1):7-12.
142. Lundbaek K, Malmros R, Andersen HC, Orht V, Jensen VA: Hypophysectomy for diabetic angiopathy. A preliminary report. Diabetes (1962) 11:474-479.
143. Wright AD, Kohner EM, Oakley NW, Hartog M, Joplin GF, Fraser TR: Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation. Br Med J (1969) 2 653):346-348.
144. Chiarelli F, Giannini C, Mohn A: Growth, growth factors and diabetes. Eur J Endocrinol (2004) 151(Suppl 3):U109-117.
145. Joplin GF, Oakley NW, Hill DW, Kohner EM, Fraser TR: Diabetic retinopathy. II. Comparison of disease remission induced by various degrees of pituitary ablation by Y90. Diabetologia (1967) 3(4):406-412.
146. Merimee TJ: A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N Engl J Med (1978) 298(22):1217-1222.
147. Alzaid AA, Dinneen SF, Melton LJ 3rd, Rizza RA: The role of growth hormone in the development of diabetic retinopathy. Diabetes Care (1994) 17(6):531-534.
148. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science (1997) 276(5319):1706-1709.
149. Rymaszewski Z, Cohen RM, Chomczynski P: Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. Proc Natl Acad Sci USA (1991) 88 2):617-621.
150. Dills DG, Moss SE, Klein R, Klein BE: Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes (1991) 40(12):1725-1730.
151. Merimee TJ: Diabetic retinopathy. A synthesis of perspectives. N Engl J Med (1990) 322(14):978-983.
152. Lauszus FF, Klebe JG, Bek T, Flyvbjerg A: Increased serum IGF-I during pregnancy is associated with progression of diabetic retinopathy. Diabetes (2003) 52(3):852-856.
153. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol (1998) 116 7):874-886.
154. Chantelau E, Kohner EM: Why some cases of retinopathy worsen when diabetic control improves. BMJ (1997) 315 7116):1105-1106.
155. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J: Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: Comparative studies with basic fibroblast growth factor. Diabetologia (1993) 36(4):282-291.
156. Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP: Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol (2004) 165(2):457-469.
157. Simpson HL, Umpleby AM, Russell-Jones DL: Insulin-like growth factor-I and diabetes. A review. Growth Horm IGF Res (1998) 8(2):83-95.
158. Jeffcoate W: Can growth hormone therapy cause diabetes? Lancet (2000) 355(9204):589-590.
159. Grant M, Jerdan J, Merimee TJ: Insulin-like growth factor-I modulates endothelial cell chemotaxis. J Clin Endocrinol Metab (1987) 65(2):370-371.
160. Grant MB, Guay C, Marsh R: Insulin-like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells. Curr Eye Res (1990) 9 4):323-335.
161. Schultz GS, Grant MB: Neovascular growth factors. Eye (1991) 5(2):170-180.
162. Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Losche C, Rollmann R, Schatz H: Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest (1993) 92 6):2620-2625.
163. Burgos R, Mateo C, Canton A, Hernandez C, Mesa J, Simo R: Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: A case-control study. Diabetes Care (2000) 23(1):80-83.
164. Spranger J, Buhnen J, Jansen V, Krieg M, Meyer-Schwickerath R, Blum WF, Schatz H, Pfeiffer AF: Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy. Horm Metab Res (2000) 32(5):196-200.
165. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA (2001) 98 10):5804-5808.
166. Danis RP, Bingaman DP: Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology (1997) 104(10):1661-1669.
167. Grant MB, Caballero S, Millard WJ: Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: A potential treatment for ocular neovascularization. Regul Pept (1993) 48(1-2):267-278.
168. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Senger DR: Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med (1999) 5 12):1390-1395.
169. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, Kahn CR: Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest (2003) 111(12):1835-1842.
170. Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, George M, Llombart C, Casellas A, Costa C, Bosch A et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest (2004) 113 8):1149-1157.
171. Sall JW, Klisovic DD, O'Dorisio MS, Katz SE: Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp Eye Res (2004) 79(4):465-476.
172. Higgins RD, Yan Y, Schrier BK: Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res (2002) 74(5):553-559.
173. Grant MB, Caballero S: Somatostatin analogues as drug therapies for retinopathies. Drugs Today (Barc) (2002) 38 11):783-791.
174. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group: The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology (2001) 108(12):2266-2272.
175. Kirkegaard C, Norgaard K, Snorgaard O, Bek T, Larsen M, Lund-Andersen H: Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenh) (1990) 122(6):766-772.
176. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, Vague P: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metabol (1992) 18(6):438-444.
177. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE: Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res (2001) 33(5):300-306.
178. Grant MB, Mames RN, Fitzgerald C: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study. Diabetes Care (2000) 23(4):504-509.
179. Tombran-Tink J, Johnson LV: Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci(1989) 30(8):1700-1707.
180. Tombran-Tink J, Chader GG, Johnson LV: PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res (1991) 53(3):411-414.
181. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science (1999) 285(5425):245-248.
182. Stellmach V, Crawford SE, Zhou W, Bouck N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA (2001) 98(5):2593-2597.
183. Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, Uetama T, Hayano M, Murota SI, Mochizuki M: Novel mechanism for age-related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol (2001) 189 3):323-333.
184. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J: Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett (2001) 489(2-3):270-276.
185. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M: Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol (2002) 134(3):348-353.
186. Spranger J, Osterhoff M, Reimann M, Mohlig M, Ristow M, Francis MK, Cristofalo V, Hammes HP, Smith G, Boulton M, Pfeiffer AF: Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes (2001) 50 12):2641-2645.
187. Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, Bouck N: Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia (2003) 46 3):394-400.
188. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY: Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA (2004) 101(17):6605-6610.
189. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J, Mori K, Yang HS, Zack DJ, Ettyreddy D, Brough DE et al: Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol (2001) 188(2):253-263.
190. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA: Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci (2002) 43(7):2428-2434.
191. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU: Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther(2001) 12(16):2029-2032.